These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 9497544)
1. [Antithrombin III concentrate use in patients with cirrhosis with coagulation disorders]. Ribeiro AA; Lourenço DM; Toledo CF; Noguti MA; Borges DR Rev Assoc Med Bras (1992); 1997; 43(3):189-94. PubMed ID: 9497544 [TBL] [Abstract][Full Text] [Related]
2. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. Langley PG; Hughes RD; Forbes A; Keays R; Williams R J Hepatol; 1993 Mar; 17(3):326-31. PubMed ID: 8315261 [TBL] [Abstract][Full Text] [Related]
3. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Fourrier F; Chopin C; Huart JJ; Runge I; Caron C; Goudemand J Chest; 1993 Sep; 104(3):882-8. PubMed ID: 8365305 [TBL] [Abstract][Full Text] [Related]
4. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Schwartz RS; Bauer KA; Rosenberg RD; Kavanaugh EJ; Davies DC; Bogdanoff DA Am J Med; 1989 Sep; 87(3B):53S-60S. PubMed ID: 2679072 [TBL] [Abstract][Full Text] [Related]
5. [The effect of substitution with AT III- and PPSB-concentrates in patients with terminal liver insufficiency]. Scherer R; Gille A; Erhard J; Paar D; Kox WJ Anaesthesist; 1994 Mar; 43(3):178-82. PubMed ID: 8179167 [TBL] [Abstract][Full Text] [Related]
6. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Büller HR; ten Cate JW Am J Med; 1989 Sep; 87(3B):44S-48S. PubMed ID: 2679070 [TBL] [Abstract][Full Text] [Related]
7. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. Dickneite G; Leithäuser B Arterioscler Thromb Vasc Biol; 1999 Jun; 19(6):1566-72. PubMed ID: 10364091 [TBL] [Abstract][Full Text] [Related]
8. Antithrombin III in Sepsis. New evidences and open questions. Ostermann H Minerva Anestesiol; 2002 May; 68(5):445-8. PubMed ID: 12029261 [TBL] [Abstract][Full Text] [Related]
9. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III. Aoki Y; Ohishi R; Takei R; Matsuzaki O; Mohri M; Saitoh K; Gomi K; Sugihara T; Kiyota T; Yamamoto S Thromb Haemost; 1994 Apr; 71(4):452-5. PubMed ID: 8052962 [TBL] [Abstract][Full Text] [Related]
10. Transfusion studies in patients with familial antithrombin III (ATIII) deficiency: half-disappearance time of infused ATIII and influence of such infusion on platelet life-span. Winter JH; Fenech A; Bennett B; Douglas AS Br J Haematol; 1981 Nov; 49(3):449-53. PubMed ID: 7295588 [TBL] [Abstract][Full Text] [Related]
11. The use of antithrombin III (ATIII) for disseminated intravascular coagulation (DIC) during septic shock. Cohendy R; Lefrant JY; de la Coussaye JE Intensive Care Med; 1998 Dec; 24(12):1344. PubMed ID: 9885894 [No Abstract] [Full Text] [Related]
12. Antithrombin III in patients admitted to intensive care units: a multicenter observational study. Messori A; Vacca F; Vaiani M; Trippoli S; Crit Care; 2002 Oct; 6(5):447-51. PubMed ID: 12398786 [TBL] [Abstract][Full Text] [Related]
13. Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin. Kamikubo Y; Hamuro T; Matsuda J; Shinya N; Miyamoto S; Funatsu A; Kato H Thromb Haemost; 1996 Oct; 76(4):621-6. PubMed ID: 8903006 [TBL] [Abstract][Full Text] [Related]
14. [Antithrombin III dosage using the chromogenic substrate Tos-Gly-Pro-Arg-NAN, in several pathological situations]. Lourenço DM; Noguti MA; Juliano L Rev Assoc Med Bras (1992); 1995; 41(6):373-8. PubMed ID: 8733245 [TBL] [Abstract][Full Text] [Related]
15. AGA Clinical Practice Update: Coagulation in Cirrhosis. O'Leary JG; Greenberg CS; Patton HM; Caldwell SH Gastroenterology; 2019 Jul; 157(1):34-43.e1. PubMed ID: 30986390 [TBL] [Abstract][Full Text] [Related]
16. [The effect of antithrombin iii concentrations during cardiopulmonary surgery]. Sonzogni V; Bellavita P; Carrara B; Cossolini M; Ferri F; Fabretti F; Mamprin F; Pelliccioli I Minerva Anestesiol; 2000; 66(1-2):17-23. PubMed ID: 10736978 [TBL] [Abstract][Full Text] [Related]
17. Antithrombin III infusion suppresses the hypercoagulable state in adult acute lymphoblastic leukaemia patients treated with a low dose of Escherichia coli L-asparaginase. A GIMEMA study. Mazzucconi MG; Gugliotta L; Leone G; Dragoni F; Belmonte MM; De Stefano V; Chistolini A; Tura S; Mandelli F Blood Coagul Fibrinolysis; 1994 Feb; 5(1):23-8. PubMed ID: 7514043 [TBL] [Abstract][Full Text] [Related]
18. Optimizing risk stratification in portal vein thrombosis after splenectomy and its primary prophylaxis with antithrombin III concentrates and danaparoid sodium in liver cirrhosis with portal hypertension. Kawanaka H; Akahoshi T; Itoh S; Iguchi T; Harimoto N; Uchiyama H; Yoshizumi T; Shirabe K; Takenaka K; Maehara Y J Am Coll Surg; 2014 Nov; 219(5):865-74. PubMed ID: 25256370 [TBL] [Abstract][Full Text] [Related]
19. A prospective randomized double-blind trial of antithrombin III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Haire WD; Ruby EI; Stephens LC; Reed E; Tarantolo SR; Pavletic ZS; Bierman PJ; Bishop M; Kessinger A; Vose J; Armitage JO Biol Blood Marrow Transplant; 1998; 4(3):142-50. PubMed ID: 9923412 [TBL] [Abstract][Full Text] [Related]
20. Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome. Vaziri ND; Paule P; Toohey J; Hung E; Alikhani S; Darwish R; Pahl MV Arch Intern Med; 1984 Sep; 144(9):1802-3. PubMed ID: 6477000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]